CRISPR Therapeutics reports third-quarter loss per share of $1.15
Story updates
09:02:11 PM UTC
SquawkNews
CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and near
09:08:35 PM UTC
SquawkNews
Crispr Therapeutics 3Q Rev $12.7M >CRSP
09:09:11 PM UTC
SquawkNews
CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 —— CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years o…
09:22:45 PM UTC
SquawkNews
CRISPR Therapeutics reported third-quarter 2026 revenue of $12.7M, up from $0.9M a year earlier, primarily reflecting recognition of $12.3M in previously deferred Vertex collaboration revenue. Net loss widened to $111.4M from $106.4M, while diluted loss per share narrowed to $(1.15) from $(1.17).Fi…